Effect of Different Dosages of Paraxanthine, the Major Caffeine Metabolite, on Energy and Focus

Sponsored by Iovate Health Sciences International Inc

About this trial

Last updated 3 years ago

Study ID

20329

Status

Completed

Type

Interventional

Phase

N/A

Placebo

Yes

Accepting

18 to 35 Years

All Sexes

Trial Timing

Ended 3 years ago

What is this trial about?

Research has shown that acute ingestion of Paraxanthine (1,7-dimethylxanthine, PXN) can enhance various markers of focus, including memory, reaction time, and attention in healthy adults. To assess these effects, this placebo-controlled crossover trial will compare the effects of 200 and 300mg of PXN to a placebo control. Participants will abstain from caffeine for 3 days, before taking the first test/placebo product for 3 consecutive days. Participants will complete questionnaires at 30, 60, 90, and 120 minutes after ingestion on Day 1 and Day 3 of ingestion. Participants will have a 3-day washout period before trialing the next test product/placebo.

What are the participation requirements?

Inclusion Criteria

* Aged between 18-35

* Willing to abstain from caffeine-containing beverages and foods during the duration of the study

* Recreationally active; currently performing structured exercise (e.g., running, weightlifting, team-sport activity) at least 2 days per week for the previous 3 months

Exclusion Criteria

* Body Mass Index: >29.9kg/m2

* Inability to adhere to protocol guidelines (e.g., caffeine, alcohol, tobacco)

* Regular tobacco use

* Illicit drug use (e.g., growth hormone, testosterone, etc.)

* A diagnosed medical condition under the care of a physician (e.g. type 2 diabetes) Inability to abstain from supplements (e.g. protein, creatine, HMB, BCAA, phosphatidic acid, etc.) at least three weeks before the trial

* Individuals on medications known to affect caffeine metabolism (e.g., corticosteroids, non-steroidal anti-inflammatories, or prescription-strength acne medications)

* Participants who are amenorrheic (females only)

* Inability to comply with the study protocol as judged by the investigators